Figures
Abstract
Background
To quantify the effect of a combination treatment of intravitreal triamcinolone acetonide (IVTA) injection, panretinal photocoagulation (PRP), and macular photocoagulation (MPC) in patients with proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).
Methodology/Principal Findings
We conducted a meta-analysis and searched for reports concerning IVTA injection combined with PRP for the treatment of PDR and DME using Medline, EMbase, Web of Science, the Cochrane Library, and Google according to Cochrane evaluation guidelines. The quality of the reports was evaluated using the Jadad score. Only four studies were ultimately included in this meta-analysis and the fixed-effects model was used. Treatment with IVTA injection combined with PRP and MPC significantly improved BCVA (p<0.001) from one to six months, compared with PRP and MPC alone. There was a statistically significant mean difference in central macular thickness (CMT), at the one-month follow-up (p<0.001). No evidence of publication bias was present. There was a low level of heterogeneity in this group of studies.
Citation: Liu L, Wu X, Geng J, Yuan Z, Chen L (2012) IVTA as Adjunctive Treatment to PRP and MPC for PDR and Macular Edema: A Meta-Analysis. PLoS ONE 7(9): e44683. https://doi.org/10.1371/journal.pone.0044683
Editor: Franco Folli, University of Texas Health Science Center at San Antonio, United States of America
Received: June 13, 2012; Accepted: August 6, 2012; Published: September 4, 2012
Copyright: © Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by three grants: (1) Liaoning Science and Technology Project, (Project Number: 2009225005); (2) Liaoning Department of Health Medical Peak of Construction Project, (Project Number: 2010016); (3) The Important Platform of Science and Technology Foundation for Universities, Department of Education, Liaoning Province government, China, (Project Number: 2011195). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Diabetic retinopathy (DR) is one of the foremost causes of blindness in the working age group [1]. Many patients with proliferative diabetic retinopathy (PDR) may also have diabetic macular edema (DME) due to DR in either eye [2]. As is well known, panretinal photocoagulation (PRP) can reduce the risk of severe visual loss in patients with high-risk PDR [3], [4], [5], but PRP sometimes causes or aggravates macular edema (ME), which is the main cause of visual reduction. Even though macular photocoagulation (MPC) (focal/grid laser photocoagulation) seems to effectively treat ME, the timing of PRP may be delayed because it should be performed after sufficient stabilization of ME [6].
A previous study demonstrated that IVTA injection may improve inflammatory, edematous, and neovascular ocular conditions [7], and IVTA injection has been used to treat ME combined with MPC. A hypothesis was formed that IVTA injection may have an additive effect with the standard treatment (PRP and MPC) with respect to visual acuity (VA) improvement, and central macular thickness (CMT) reduction [8]. Studies were carried out to clarify this, but the conclusions were inconsistent.
To quantify the effect of a combination treatment of IVTA injection and PRP and MPC on patients with PDR and DME, we performed a meta-analysis of randomized controlled trials (RCTs), and assessed the BCVA and CMT after intravitreal triamcinolone combined with PRP and MPC laser-refractory PDR and DME.
Methods
This meta-analysis was performed according to a predetermined protocol described previously in QUOROM statement and MOOSE recommendations [9], [10].
Search Strategy
Two researchers (Lei Liu, Jin Geng) independently searched the literature using the following electronic databases: MEDLINE, EMBASE, Web of Science, Google (Scholar), and the Cochrane Library. Manual searching of bibliographies was also performed. All published and internet-accessible articles (as on the 10 April 2012) were considered. For maximum sensitivity, the search strategy for free text and thesaurus terms included ‘triamcinolone’, ‘diabetic retinopathy’, and ‘panretinal photocoagulation’. The dates for the MEDLINE search were 1950 to April 2012, the dates for the EMBASE search were 1998 to April 2012, and the Cochrane Library and Google (Scholar) were accessed on 10 April 2012. Full articles were retrieved, when titles and/or abstracts met the study objective. All published studies that evaluated IVTA injection combined with PRP and MPC treatment for PDR were included, if they met the criteria. The search included only RCTs. At least one or more clinical outcome representing intraoperative and/or postoperative outcome parameters had to have been assessed and published. There was no language restriction on the publications.
Inclusion and Exclusion Criteria
Articles potentially eligible for inclusion in this meta-analysis were RCTs on IVTA injection combined with PRP and MPC therapy for PDR and DME published up to April 2012.
Exclusion criteria were: causes of macular edema other than diabetic retinopathy, when triamcinolone was not used as an adjunct to PRP, and republication articles. In addition, articles were excluded if they did not satisfy one or more inclusion criteria.
Data Extraction
Data were extracted from each article using a standardized form including: (1) general data: title, authors, publication date, resource; (2) subjects, intervention measures, quality control; and (3) outcomes.
The four trials that were included in the meta-analysis presented comparable data suitable for quantitative statistical analysis.
Outcome measures
BCVA of logarithm of the minimum angle of resolution (logMAR) units, CMT, intraocular presser (IOP), standard central macular thickness (SCMT), total macular volume (TMV), any changes in VA compared with the pre-injection level, and complications after therapy, were evaluated following IVTA injection combined with PRP and MPC for treatment of PDR and DME in the various outcomes from the different articles.
Quality Assessment of Retrieved Articles
Methodological quality was assessed by methods of random allocation, allocation sequence concealment, blinding and missing data on follow-up using the Jadad Score [11]. High quality was previously defined as a Jadad score more than three.
Data Analysis
RevMan 5.0 statistical software offered by the Cochrane collaboration net was used to analyze the data. The treatment effects were calculated as weighted averages of the mean difference in logMAR visual acuity between study and control groups (weighted mean difference method).
All meta-analyses were evaluated for heterogeneity using the Q statistic of the Chi-square test (χ2) value test and I2 test [12].
I2 estimated the percentage of the total variance in all of the data under consideration that was related to heterogeneity. The authors suggested using 25%, 50%, and 75% to indicate low, moderate or high levels of heterogeneity. If there was a moderate or high level of heterogeneity, a random-effects meta-analysis was performed by the DerSimonian and Laird method unless using the fixed-effects models. Publication bias was assessed by visually inspecting a funnel plot. A p value less than 0.05 was considered statistically significant [13], [14].
Results
A total of 32 articles that were potentially relevant were identified and screened for retrieval (Table 1). After systematic review, only four studies were ultimately included in the meta-analysis. The progress for study inclusion is shown in Figure 1. One of the trials was performed in Europe, two in Asia, and the other was in South America. Two studies were unclear blinding, and 59 eyes were included in the meta-analysis. The dose for the IVTA injection was 4 mg. Mean follow-up was 8.25 (SD 4.5) months. BCVA and CMT were common outcomes, and we evaluated these in our meta-analysis. The characteristics for each study are shown in Table 2.
VA was the most important criterion for evaluating efficacy. In all of the studies, BCVA was reported as a mean change in logMAR units, and measured by logMAR scale from baseline to follow-up months. Pooling the results revealed that at one-month follow-up, treatment with IVTA injection combined with PRP and MPC (study group) significantly improved BCVA compared with PRP and MPC alone (control group) (WMD, −0.19; 95%CI, −0.27 to −0.11; p<0.01). Similar efficacy was found at six months (WMD, −0.16; 95%CI, −0.21 to −0.10; p<0.01), and 12 months (WMD, −0.20; 95%CI, −0.27 to −0.13; p<0.01) (Figure 2).
BCVA = best-corrected visual acuity; IVTA = intravitreal injection of triamcinolone acetonide; MPC = macular photocoagulation; PRP = pan-retinal photocoagulation; SD = standard deviation; IV = weighted mean difference; CI = confidence interval; df = degrees of freedom; Chi2 = chi-square statistic; p = p value; I2 = I-square heterogeneity statistic; Z = Z statistic.
CMT is considered a strong prognostic measure for levels of ME, so it was also assessed in this meta-analysis. CMT was reported as the mean change from baseline to follow-up months and was measured by optical coherence tomography (OCT). The pooled results revealed that at one-month follow-up, treatment in the study group significantly improved CMT, compared with the control group (WMD, −70.56; 95%CI, −89.92 to −51.19; p<0.01). Similar efficacy was found at three months (WMD, −66.08; 95%CI, −85.07 to −47.10; p<0.01) and six months follow-up (WMD, −55.29; 95%CI, −78.38 to −32.20; p<0.01) (Figure 3).
CMT = central macular thickness; IVTA = intravitreal injection of triamcinolone acetonide; MPC = macular photocoagulation; PRP = pan-retinal photocoagulation; SD = standard deviation; IV = weighted mean difference; CI = confidence interval; df = degrees of freedom; Chi2 = chi-square statistic; p = p value; I2 = I-square heterogeneity statistic; Z = Z statistic.
There were no complications in these four studies. IOP was mentioned in all four studies, thus IOP was assessed in the meta-analysis. However, at six months follow-up, there were no significant differences in IOP in the study group compared with the control group (WMD, 0.55; 95%CI, −0.55.to 1.65; p<0.01) (Figure 4). In addition, only one study reported that two ITVA eyes had significant cataract progression.
IOP = intraocular pressure; IVTA = intravitreal injection of triamcinolone acetonide; MPC = macular photocoagulation; PRP = pan-retinal photocoagulation; SD = standard deviation; IV = weighted mean difference; CI = confidence interval; df = degrees of freedom; Chi2 = chi-square statistic; p = p value; I2 = I-square heterogeneity statistic; Z = Z statistic.
All study comparisons passed the test of heterogeneity, as previously defined. Fixed-effects models were used for the meta-analysis. There was no significant publication bias in this meta-analysis. The funnel plot of randomized controlled trials and a risk of bias for publication summary following a bias-risk evaluation are shown in Figure 5.
Risk of bias summary across all studies; ‘+’: present; ‘−’: absent; ‘?’: questionable(B).
Discussion
This meta-analysis revealed that ITVA combined with PRP and MPC was an effective treatment for PDR and DME. Three of the reported studies (Bandello F et al. [15], Choi KS et al. [8], and Maia OO Jr et al. [16]) confirmed that ITVA combined with PRP and MPC was effective for treating PDR and DME, but the conclusions of Mirshahi A et al. [17] were not in accordance. Thus, we conducted this meta-analysis to clarify whether ITVA injection combined with PRP and MPC was effective for the treatment of PDR and DME.
TA is commonly used to treat ME in the clinical situation, and IVTA has been shown to be useful in the reduction of CMT caused by DME [18].
As we know, new vessel formation stimulated by vascular endothelial growth factor (VEGF) is the major pathology underlying PDR. In addition, studies have suggested that IVTA is clinically effective in inhibiting the metabolic pathway of VEGF, and in anti-inflammatory, edematous, neovascular, and proliferative disorders [19], [20]. PRP is recommended as an effective method to prevent neovascularization and progression of PDR, but aggravation of ME with a decrease in VA can occur in DR after PRP. There has thus been an initiative to study the effect of IVTA combined with PRP and MPC on PDR and DME in patients.
As a result of structural changes caused by poorly controlled diabetes, Mirshahi A et al. reported that IVTA combined with PRP and MPC did not have a significant beneficial effect on BCVA improvement and CMT reduction in coexisting PDR and DME, compared with PRP and MPC as a standard treatment in these patients [17].
Our meta-analysis for all logMAR scales of BCVA during follow-up months revealed that IVTA injection combined with PRP and MPC could improve BCVA for PDR and DME. CMT is an important criterion for evaluating ME and was assessed during follow-ups. We revealed that IVTA injection combined with PRP and MPC could reduce CMT in PDR and DME. The reason for the efficacy of TA is that it improves inflammation and changes in retinal blood flow associated with photo-oxidative reactions induced by laser-tissue interactions [21]. Wilson et al. reported that an intravitreal steroid in an animal (rabbit) model reduced the blood retinal barrier breakdown that was induced by retinal photocoagulation [22].
In the study by Maia OO Jr et al. [16] IVTA was carried out before PRP and MPC. However, in the other three studies IVTA was carried out after PRP and MPC. Therefore, the study by Maia OO Jr et al. may have introduced methodological bias in the analysis, but after considering all the other inclusion criteria, we included it in this meta-analysis. Prospective studies are needed to evaluate the efficacy of different methods.
There were some limitations to this study: (1) Only a small number of trials were enrolled in this meta-analysis; (2) There were short, and different follow-up times for observation; (3) Only two common outcomes were evaluated; (4) As we cannot attempt to gain access to unpublished results, publication bias cannot be fully excluded.
As far as we know, this is the first systematic review specifically answering the question of whether the combined treatment method of IVTA injection with PRP and MPC is effective for treating PDR and DME. Even with the limitations, we feel the conclusions of this meta-analysis are clinically useful for treatment considerations.
In conclusion, IVTA injection combined with PRP and MPC may represent a new strategy to more effectively treat PDR and DME. RCTs with larger sample sizes, possibly multicenter trials, and longer follow-up times are needed to better evaluate the benefits and safety of IVTA injection combined with PRP and MPC for PDR and DME.
Acknowledgments
Thanks to Jingpu Shi, Ph.D, Professor of the Department of Clinical Epidemiology and Evidence Medicine in the First Affiliated Hospital of China Medical University. Thanks also to the editors and anonymous reviewers.
Provenance and peer review
Not commissioned; externally peer reviewed.
Author Contributions
Conceived and designed the experiments: LL LC. Performed the experiments: LL LC ZY. Analyzed the data: XMW LL JG. Contributed reagents/materials/analysis tools: XMW LL LC. Wrote the paper: LL LC.
References
- 1. Yamada M, Hiratsuka Y, Roberts CB, Pezzullo ML, Yates K, et al. (2010) Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol 17: 50–57.
- 2.
Report of a WHO consultation in Geneva (2006) Geneva Switzerland: 2006. World Health Organization. Recommendations in Prevention of Blindness from Diabetes Mellitus; 3–5.
- 3. Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy, ETDRS report number 9. Ophthalmology 98: 766–785.
- 4. Diabetic Retinopathy Study Research Group (1976) Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81: 383–396.
- 5. Diabetic Retinopathy Study Research Group (1981) Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS): DRS report 8. Ophthalmology 88: 583–600.
- 6. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, et al. (2003) Quantifying alterations of macular thickness before and after pan-retinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 110: 2386–22394.
- 7. Avci R, Kaderli B (2006) Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol 244: 28–35.
- 8. Choi KS, Chung JK, Lim SH (2007) Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema. Korean J Ophthalmol 21: 11–17.
- 9. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. (1999) Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896–1900.
- 10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
- 11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
- 12. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
- 13. Mantel J, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
- 14. Der Simonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
- 15. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, et al. (2006) Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 124: 643–650.
- 16. Maia OO Jr, Takahashi BS, Costa RA, Scott IU, Takahashi WY (2009) Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol 147: 291–297.
- 17. Mirshahi A, Shenazandi H, Lashay A, Faghihi H, Alimahmoudi A, et al. (2010) Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 30: 254–259.
- 18. Jonas JB, Söfker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132: 425–427.
- 19. Jonas JB, Kreissig I, Degenring R (2005) Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 24: 587–611.
- 20. Fischer S, Renz D, Schaper W, Karliczek GF (2001) In vitro effects of dexamethasone on hypoxia-induced permeability and expression of vascular endothelial growth factor. Eur J Pharmacol 411: 231–243.
- 21. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Nishijima K, et al. (2002) Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci 43: 1204–1209.
- 22. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, et al. (1992) Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 110: 1155–1159.